Back to results
US 11,231,426 B2Granted
Methods and compositions for monitoring phagocytic activity
AssigneeInven2 AS
InventorsTormod Fladby, Lisbeth Johnsen, Hanne Mali Mollergard
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for monitoring phagocytic activity (e.g., diseases and conditions relating to phagocytic activity). In particular, the invention relates to compositions and methods for diagnosing, monitoring, and/or assessing risk of neurodegenerative diseases (e.g., AD).
Claims12
A method for detecting peptides in a sample, said method comprising:
- a) obtaining a blood sample from a patient, said sample comprising a cell type selected from the group consisting of leucocytes, monocytes, peripheral blood macrophages, and activated macrophages from peripheral blood;
- and
- b) detecting the presence of a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:5 in said cell type selected from the group consisting of leucocytes, monocytes, peripheral blood macrophages, and activated macrophages from peripheral blood said peptide has both n-terminal and c-terminal truncations as compared to Aβ42.
A method for detecting the presence of a peptide in a sample consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:5:
- a) obtaining a blood sample from a patient, said sample comprising a cell type selected from the group consisting of leucocytes, monocytes, peripheral blood macrophages, and activated macrophages from peripheral blood;
- b) isolating said cell type selected from the group consisting of leucocytes, monocytes, peripheral blood macrophages, and activated macrophages from peripheral blood;
- and
- c) detecting the presence of said peptide in said isolated cell type selected from the group consisting of leucocytes, monocytes, peripheral blood macrophages, and activated macrophages from peripheral blood, wherein said peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:4 and SEQ ID NO:5 and wherein said peptide has both n-terminal and c-terminal truncations as compared to Aβ42.
1 more element
Dependencies are inferred from the claim text.